McDermott Will & Emery advised Dynacure, a company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have few or no treatment options, on its cross-border merger with the Belgian company Flamingo Therapeutics, to create a leading RNA therapeutics company focused on clinical oncology.
The combined company will be named Flamingo Therapeutics and will focus on advancing Flamingo Therapeutics’ asset danvatirsen in a Phase II trial PEMDA-HN in Head & Neck cancer and IND-ready program targeting MALAT-1 (FTX-001), in oncology.
The merger leverages common synergies of Flamingo Therapeutics and Dynacure, including deep expertise in RNA-targeting and clinical drug development.
The McDermott team that advised Dynacure was composed of :
• Emmanuelle Trombe, partner, on Life Sciences aspects
• Nicolas Lafont, partner, Paul Lozniewski, Lucie Martin and Clarice Duclos, associates, on Corporate aspects
• Côme de Saint Vincent, counsel, and Paul-Henry de Laguiche, associate, on Tax aspects
• Jilali Maazouz, partner, and Nicolas Chaubet, associate, on Employment law aspects.